The DNA extraction was performed as previously described (Lin et al, 1993) . Total RNA was purified from cancerous and nearby non-cancerous tissues and peripheral mononuclear cells using a commercial kit (RNAzolTMB, Biotecx laboratories, Houston, TX, USA). RNA was stored as a pellet in ethanol or solubilized in RNAase-free water and kept at Ð70°C. Reverse transcription was performed as described previously (Chen et al, 1997) .
Reverse transcription polymerase chain reaction (RT-PCR), long PCR, Southern blot analysis and sequencing
The primers used for RT-PCR analysis of the TSG101 gene are shown in Table 1 . The PCR conditions were as described, but with some modifications (Chen et al, 1997) . Briefly, 1 µl of cDNA was used for the first PCR amplification in a volume of 100 µl -+  3  56  SCC/III  IB 1 ,IA 4  -ID,IA 1 ,IA 4  -4  42  SCC/III  IA 1 ,IB 2 ,IIB,IA 3  ---5  28  SCC/II  IA 3 ,IA 1  +  I A 1 ,IC,IID  +  6  67  SCC/III  IB 2 ,IIL  +  IID  +  8  36  SCC/II  IB 2 ,IIB,IA 3  +  I B 2 ,IA 1  +  9  31  SCC/II  IB 1 ,IB 2  +  IIH  +  13  59  SCC/III  IB 2 ,IA 1  +  I A 1  +  14  36  SCC/II  IE  +  IIM  +  15  73  SCC/II  IB 2 ,IIK,IA 1  -II I,IID  -16  63  SCC/II  IB 2  +  --17  67  SCC/II  IA 1 ,IA 4  ---18  50  SCC/III  IIM  +  IA 4  +  19  48  SCC/II  IID,IA 1 ,IIA  +  IIF,IA 1  +  20  48  SCC/III  IE,IB 2 ,IA,IIF  +  IE,IA 1  +  21  35  SCC/II  IB 2 ,IID  +  IIF,IIE,IB 1 ,IIA,IA 1 ,IA 4  +  22  56  SCC/III  IID,IE,IB 2 ,IB 1 ,IA 1 ,IA 4 ,  +  IE,IB 2 ,IIA, IA containing 100 ng each of primers P1u and P1d, 50 µM of each dNTP, 1 × PCR buffer, and 2.5 units polymerase. PCR was performed for 35 cycles of 1.5 min at 94°C for denaturation, 1.5 min at 56°C for annealing, and 2.5 min at 72°C for extension, with a final extension of 5 min at 72°C using a Perkin-Elmer Cetus PCR Thermocycler. Of the first PCR products, 1Ð10 µl were subjected to a second round of PCR amplification using nested primers P2u and P2d for 35 cycles under the above conditions. The PCR products were electrophoresed and analysed using agarose gel. For long PCR, amplification of genomic DNA, the primers and PCR conditions were identical to the study of Li et al, 1997) . We also used the primer located near the breakpoint regions to amplify the breakpoints (Table 1 ). The PCR products of nested RT-PCR and long PCR were subjected to Southern blot analysis as follows: the DNA on agarose gel was Southern transferred to a nylon membrane. The membrane was hybridized with a random-primer 32 P-labelled probe (DECA primer II DNA labelling kit, Ambion, Austin, TX, USA) which corresponded to the cDNA of TSG101. All positively labelled fragments were subjected to isolation and sequencing analysis. Isolation was achieved by electrophoresis in a 3% low melting agarose gel; the fragments were excised after separation. They were then purified using a commercial kit (Qiaex II gel extraction kit, Qiagen, Chatsworth, CA, USA), and the purified fragments were sequenced by the cycling sequencing method using an ABI 310 automatic sequencer. The sequencing primers are also shown in the Table 1 .
Southern blot analysis of genomic DNA
Genomic DNA (5Ð10 µg) was digested with restriction enzymes EcoRI, HindIII and SacI according the manufacturerÕs instructions, electrophoresed in 0.8% agarose gel, Southern transferred to Hybond H+ membrane, fixed by UV cross-linking, and the membrane was hybridized with a random-primer 32 P-labelled cDNA probe as mentioned above. Loss or gain of restriction fragments was assessed by visual comparison of hybridization signals after developing the exposed radiographic film.
Human papillomavirus (HPV) analysis
The HPV DNA sequence in tumour samples was amplified using the pU-1M/PU-2R primer pair to amplify malignant HPV DNA (HPV 16, 18, 31, 33, 52b and 58) ; benign HPV DNA (HPV 6 and 11) was amplified using the pU-31B/pU-2R primer pair. The primers and PCR procedures were identical to those used in the study of Fujinaga et al (1991) .
RESULTS

RT-PCR amplification and sequence analysis
RT-PCR analysis and sequencing of the PCR fragments revealed frequent expression of both the wild-type TSG101 and intragenic deletions in cancerous and non-cancerous tissues. The results of M  C1  N1  C2  N2  C3  N3  C4  N4  C5  N5  C6  N6  C7  N7  C8  N8   700  600  500  400  300  200   100   M  C9  N9  C10  N10  C11  N11  C12  N12  C13  N13  C14  N14  C15  N15  C16  N16   700  600  500  400 In addition to the wild-type transcript, most cancerous tissues (100% of cervical carcinomas and 80% of endometrial carcinomas) as well as most of the non-cancerous tissues (73.7% of nearby cervical tissues and 80% of paired endometrial tissues) demonstrated one or more aberrant TSG101 transcripts (Figure 1 ). The aberrant band sizes were diverse (120Ð881 bp) with a range of one to six bands in any one specimen. Upon sequencing, we found that the aberrant bands were due to intragenic deletions, including 25 different types of deletion and deletion sizes range from 387 bp to 1075 bp. According to region, at least three major categories of deletion could be found. Group 1 was similar to those found by Lee and Feinberg (1997) , and may be due to relaxation of the splicing mechanism (Figure 3 , type 1). Group 2 had a common homologous sequence between the donor and acceptor area ( Figure 3 , type II). Group 3 had a deletion and an insertion ( Figure  3 , type III). Cancerous and non-cancerous tissues did not differ in the types of deletions found. The sequencing results of aberrant bands are shown in Table 2 and Figure 2 .
Genomic long PCR and genomic Southern blot analysis
For further analysis of the breakpoint, we followed long PCR method as described by Li et al (1997) . At the expected breakpoint site on the gel, no PCR products could be found with TSG101 There are three types of aberrant transcripts. Type I has a splicing donor or acceptor site sequence at the deletion junction region. Type II has a homologous sequence between the deletion junction region. Type III has both deletion and insertion cDNA probe detection (data not shown). We also used primers much closer to the intragenic deletion region to amplify the breakpoint. However, we were unable to amplify the breakpoint region.
To further demonstrate gross deletion of the TSG101 gene, we used Southern blot analysis of genomic DNA to detect deletion fragments. There were no gross deletions despite the presence of aberrant transcripts (data not shown). The lack of any altered DNA fragment on direct genomic Southern blots and long PCR analysis in any of the 19 cervical and five endometrial cancerous or noncancerous samples, including those with aberrant transcripts, indicated that the aberrant transcripts were not caused by intragenic deletion of sufficient size to explain them.
HPV analysis
None of the patients in this study with endometrial cancer had HPV infection. Of 19 patients with cervical cancers (73.7%), 14 had detectable HPV DNA, of which 11 were HPV 16, two HPV 18, one HPV16+31, one HPV 31, and one HPV 58. Of 18 noncancerous tissues, ten demonstrated HPV infection, of which five tissues were infected by HPV 16, one by HPV 18, and four by HPV 31. However, no definite relationship between HPV infection and the abnormal TSG101 transcript was found (Table 2) .
Aberrant transcripts of TSG101in normal peripheral mononuclear cells
RT-PCR analysis and sequencing of the PCR fragments in normal peripheral mononuclear cells revealed frequent expression of the wild-type and intragenic deletion of TSG101 transcripts. The results of abnormal transcript analysis are shown in the Figure 1D and Table 2 . In addition to the wild-type transcript, 9 (56.25%) out of 16 demonstrated one to four aberrant TSG101 transcripts ( Figure 1D ). Li et al (1997) , based on the presence of truncated transcripts found by RT-PCR and Southern hybridization of PCR products of genomic DNA, reported the presence of large intragenic deletions of the TSG101 gene in 7 out of 15 primary human breast cancers, but none in matched normal breast tissues. Lee et al (1997) used a similar approach to analyse 72 human breast cancer and matched noncancerous tissues. They found that the aberrant transcripts were common in both cancerous and non-cancerous tissues; no intragenic deletions were found in their cases using long PCR or Southern blot analysis of genomic DNA. Steiner et al (1997) performed Southern blot analysis of genomic DNA from human breast cancer cell lines and normal peripheral blood. They were unable to find intragenic deletion of TSG101 gene. In this study, we used a similar approach to investigate the role of TSG101 in the development of cervical and endometrial cancers. We also found that the aberrant transcripts were common in both cancerous and non-cancerous tissues, and that there were no intragenic deletions, point mutations or small deletions/insertions on genomic Southern blot analysis and whole cDNA sequencing analysis. Our results were, thus, similar to the studies of Lee et al (1997) and Steiner et al (1997) . Lee et al (1997) suggested that the relaxation of RNA splicing may, in general, contribute to abnormal gene expression. We found a new type of aberrant transcript that had a homologous sequence between donor and acceptor sites. We suggest that this type of aberrant transcript may be related to RNA secondary structure. We found some aberrant transcripts could be found at the first PCR reaction, such as deletion from nucleotide 154 to 1054 or from nucleotide 154 to 1070, which has highly homologous splicing and acceptor site-like sequence at the deletion junction. From this point of view, we suggest that the aberrant transcripts might be the result of imperfect minor splicesome products.
DISCUSSION
The aberrant splicing of TSG101 gene appears to be identified more frequently in cancerous than in non-cancerous tissues (100% vs. 72.5%), but it also appears in peripheral mononuclear cells of normal persons. For these reasons, the role of TSG101 gene as a tumour-suppressor gene cannot yet be confirmed and requires much more careful evaluation. 
